Title
Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device.

Permalink
https://escholarship.org/uc/item/2m41s1nj

Journal
PloS one, 12(4)

ISSN
1932-6203

Authors
Yoon, Jun-Hee
Kim, Thomas W
Mendez, Pedro
et al.

Publication Date
2017

DOI
10.1371/journal.pone.0174696

Peer reviewed
Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device

Jun-Hee Yoon1,2, Thomas W. Kim3, Pedro Mendez1,2, David M. Jablons1,2*, Il-Jin Kim1,2*

1 Thoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, California, United States of America, 2 Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America, 3 CureSeq Inc., Brisbane, California, United States of America

* Il-Jin.Kim@ucsf.edu (IJK); David.Jablons@ucsf.edu (DMJ)

Abstract

The development of next-generation sequencing (NGS) technology allows to sequence whole exomes or genome. However, data analysis is still the biggest bottleneck for its wide implementation. Most laboratories still depend on manual procedures for data handling and analyses, which translates into a delay and decreased efficiency in the delivery of NGS results to doctors and patients. Thus, there is high demand for developing an automatic and an easy-to-use NGS data analyses system. We developed comprehensive, automatic genetic analyses controller named Mobile Genome Express (MGE) that works in smartphones or other mobile devices. MGE can handle all the steps for genetic analyses, such as: sample information submission, sequencing run quality check from the sequencer, secured data transfer and results review. We sequenced an Actrometrix control DNA containing multiple proven human mutations using a targeted sequencing panel, and the whole analysis was managed by MGE, and its data reviewing program called ELECTRO. All steps were processed automatically except for the final sequencing review procedure with ELECTRO to confirm mutations. The data analysis process was completed within several hours. We confirmed the mutations that we have identified were consistent with our previous results obtained by using multi-step, manual pipelines.

Introduction

There were several breakthroughs for genetic and genomic analyses since the first description of DNA double helix structure in 1953 [1,2]. A development of the polymerase chain reaction (PCR) technology opened an era for different types of genetic analyses with limited amount of DNA from various biological samples [3–5]. PCR amplification technology is still a foundation of up-to-date genome analysis technologies. Sanger sequencing was then developed [6,7], and enabled a discovery of human genome sequences and completed the human genome sequence map (The Human Genome Project) in 2003 (https://www.genome.gov/10001772). The next revolution of genetic and genomic analyses would be the development of microarray or DNA
chip technology [8]. With this hybridization-based high throughput expression or genotype technologies, all known genes could be analyzed at one time for their expression. Microarray technology contributed to the identification of new subtypes and biomarkers of diseases such as cancer [8–12].

Next-generation sequencing (NGS) is the state-of-the-art technology widely used for genetic and genome analyses in many life science fields. NGS was initially developed in mid-2000’s [13–15], and aimed to sequence the genome in one experiment. Later, the same technology was adapted to allow the sequencing of the whole transcriptome, also called RNA-seq [16–19] and the epigenome [20]. The previous technologies mentioned above also had their own ‘paradigm-shifting’ and ‘revolutionary’ points. But, NGS is the first technology enabling us to sequence the whole exome or genome in one experiment [13–15]. Despite technical superiority by NGS, it was not easy to use NGS technology in a regular laboratory at the beginning for several reasons. First, it was strictly too complex. It required multiple challenging steps and relatively higher quality and quantity of DNA or RNA. Second, the cost was tremendously high. Although NGS can generate great amount of genome or exome data, the costs for reagents, chips or sequencing cells, and machines were extremely high, which prevented a frequent and regular use of NGS for various applications. Lastly, NGS data analyses or bioinformatics procedures were notoriously difficult for most biologists. As one whole exome or genome sequencing can produce up to gigabytes of data, it is overwhelming to handle by most molecular biologists or geneticists.

However, situations for NGS applications had changed dramatically for last several years. The sequencing cost has been significantly reduced from more than several thousands of dollars per exome to near one thousand dollars [21]. The size of sequencing data has also been dramatically reduced because of the increasing demand of a targeted sequencing focusing on 5–300 genes rather than exome sequencing [22–25]. Exome sequencing strategy is still invaluable for identifying new biomarkers by big research consortiums such as TCGA [26,27]. However, a targeted sequencing approach focusing only selected genes such as cancer panels or hereditary disease panels seems more dominant for precision or personalized medicine applications [22–25]. In fact, a lot of Clinical Laboratory Improvement Amendments (CLIA) labs provide a targeted sequencing panel rather than an exome or whole genome sequencing due to data accuracy, cost, and turn-around-time (TAT) [22–25]. Thus, a reduction of sequencing cost, data size, TAT, and an increase of competition among many commercial companies and CLIA labs would expedite the processes to the era of having personal sequencing information. Currently, only family members under screening programs of hereditary cancer or some already diagnosed cancer patients are genetically tested by NGS with appropriate biological samples (i.e. blood or tumor). Nevertheless, we believe that more and more people will need or want to know their genetic profiles in a near future. A successful application of circulating tumor DNA sequencing for the early detection of cancer or prognosis surveillance [28–30], supports the idea that sequencing information will be available to people who want to know it. Though, the cyber-security must be improved and there should be clear legal regulations and consensus for handling, analyzing, interpreting, and delivering the genome information as it is very massive and delicate personal information.

Although it seems very promising to see the era for a regular NGS sequencing screening testing (like X-ray), in a regular clinical laboratory, there are some significant hurdles to overcome. Those are NGS data analyses, interpretation, and reporting. There should be a robust automatic data processor from the sequencer through bioinformatics data analysis pipelines, clinical interpretation, and genetic information delivery. Many CLIA labs use different bioinformatics pipelines to analyze NGS data [22–25,31–33]. And yet, each step tends to be separated and controlled manually, possibly by different persons. After a laboratory technician...
complete the sequencing, the data quality may be checked first and then downloaded to the bioinformatics pipelines. Then Bioinformatics team starts converting the raw sequencing data into their appropriate analysis programs going through several steps such as sequence alignment, filtering, variant calling, annotation, and the final review. The selected genetic variants will be passed to the interpretation or analytics team for making a report and providing clinical or biological meanings. The finalized genetic report will then be delivered to patients or doctors via mail, e-mail, or fax. All these multiple and complex steps would be feasible only for analyzing a small scale of samples. However, if we want to handle a large number of samples accurately and robustly, this kind of currently used bioinformatics methods will be a problem.

Thus, we decide to develop an automatic NGS data analysis program which works in a mobile device (i.e. cellular phone) that controls the whole process, from the sequencing run in a sequencer through NGS data analyses to the genetic information delivery. One of challenging points for making the whole automatic process from the ‘wet’ laboratory sequencing works to the ‘dry’ bioinformatics works may be an efficient communication between wet and dry laboratories. We aim to make a simple but very useful program working in a mobile device to check and control all the processes of NGS. Though it is still preliminary to deliver the genome information directly to patient or individual due to legal issues, it may be eventually possible to get their genome information through a simple and easy way like mobile phone, not through on-site hospital visit or a regular mail delivery. Thus, it will be required to develop a comprehensive system delivering personal genome information by satisfying and keeping the rule and regulation by authorized organizations.

In this work, we present an automatic NGS data analysis processor, MGE, to show that full steps for the automatic NGS data analyses are available through a simple pipeline with mobile application and server application.

Materials and methods

An overview of the Mobile Genome Express (MGE)

The MGE system is composed with 5 steps of 1) data submission, 2) data calculation, 3) data storage, 4) data review, and 5) data display (Fig 1). These steps are organized as one pipeline called the MGE, with full automatic running system. We have developed the MGE process by using several computer languages. The smartphone application is made with Javascript and HTML5 by using Phonegap, the server side codes are made with Python and PHP5, and MGE uses MySQL for the database. Our testing server is operated by Ubuntu 14.04.

Data submission

MGE is executed in a mobile device, connected to a main server (controlled by the user) and to the sequencer. To ensure the security of the data and access of the user, an authentication system has been implemented. After logging in, MGE requires to input the internal internet protocol (IP) address of the corresponding sequencer. Once the user access the sequencer, the sequencing run to be analyzed is selectable from the run list. The user can also check some of the sequencing run features (e.g. the number of samples included in the sequencing run and their barcode number).

The integration of some of the supported Application Program Interface (API) available in the Software Development Kit (SDK) of Ion Torrent Suite (Thermo Fisher Scientific Inc.) in MGE was coded by using JavaScript Object Notation (JSON) format. Therefore, MGE smartphone application provides user interaction, and setting a target to go to next steps for user’s main server. Furthermore, we designed a sample submission form to gather experiment information in this step (Fig 2). Most information is obtained from the sequencing platform
automatically; although, the user can instead introduce the sequencing information manually through the smartphone application. Once the information is submitted, MGE transfers data from sequencer’s server to the MGE’s main server, followed by running it in an authorized path.

Data calculation

Data calculation can be customized with different plugins such as: sequencing depth calculator, low quality sequencing reads filter, variant caller, and many more. MGE manage the server’s calculation process by running PHP5 and Python codes, and can be applied in with samples automatically, since MGE passes to calculating codes file paths and essential information. After getting results in this step, server inserts data to MGE database. MGE sends notification to MGE administrator by email each time when the data calculation starts and when it ends. The recipient list of the MGE alert email, can include as many users as needed, under administrator supervision.
**Data review**

MGE has a separate web-based application to review the sample-related output sequencing data, called ELECTRO (Fig 3). The application is designed in a table-like interface, where the users can easily browse the data by user’s sequencing name, submission date, and user ID. All the tabs are sortable, which makes the data reviewing process more efficient and convenient. In addition, ELECTRO integrates an Integrative Genomic Viewer (IGV) interface, that allows the review of each called mutation, by clicking the IGV button. Once the review is finished, ELECTRO incorporates the results editor and generator, which exports the final mutation data to an independent spreadsheet file. With these features users can edit sample’s mutation status details and export the final result. ELECTRO allows the simultaneous online connection of all the data-review team members. This feature allows a real-time review of any sequencing result (Fig 3).

**Data storage**

MGE has its own database and automatically stores all the data into it, such as: sequencing file, information from sequencing data, mutation result, and final result.

Data can be stored at any step, even if the calculation is being performed. Upon data submission and calculation, MGE inserts the information to its database and user can access to...
Fig 3. Review of sequencing data in ELECTRO (MGE). (a) ELECTRO’s web interface, the MGE original sequencing data review web page. (b) Variant curation page. Important information is displayed per each variant. MGE reflects this information on final result screen on user’s smartphone and spreadsheet file. (c) Review of raw sequencing data on IGV plugin within the ELECTRO-MGE interface. Csm id: MGE own ID for a mutation; css id: MGE own ID for a sample; cosmic id: COSMIC ID; gene: Gene symbol (HGVS); CDS: CDS nomenclature of each variant; Amino Acid Change: amino acidic nomenclature of each variant; # of COSMIC samples: number of positive records of the variant in COSMIC database; # of Mutation Reads: number of sequencing reads with variant allele; # of Wildtype reads: number of sequencing reads with reference allele; VAF: variant allele frequency; Report flag (true = 1): Present decision of a mutation, 1 = true mutation, 0 = false mutation; Homopolymer status: region within a homopolymer region (Y = yes, N = no); Location: genomic coordinates (chr#:start_nt) of the variant.

https://doi.org/10.1371/journal.pone.0174696.g003
this database by ELECTRO. We built this database scheme to optimize all MGE procedure in practice.

Data distribution and security

Data distribution, the final step of MGE process, is similar to ELECTRO. The only difference is that it runs in a smartphone. MGE smartphone application can show final reviewed data such as: Catalogue of Somatic Mutations in Cancer (COSMIC) mutation ID, amino acid change and mutation’s allele frequency (Fig 4). Every information gets processed and reviewed by the bioinformatics and data reviewing specialists, and the MGE results include direct comments from the data curation team. This information can be displayed both in the smartphone and in the output spreadsheet, which is very important for a proper contextualization of each mutation and variant annotation, when needed. Moreover, read-depth report for each amplicons and quality PDF from sequencing machine are provided to users for checking sample’s quality. For information security, we used Virtual Private Network (VPN) to secure our all information and MGE can be install in VPN environment.

Targeted cancer panel sequencing

The Acrometrix Oncology Hotspot Control DNA (Thermo Fisher, Waltham, MA; Cat. No. 969056) was used for generating sequencing data for testing and evaluating MGE and ELECTRO as previously described [22]. This control DNA contains more than 500 COSMIC mutations from 53 genes (Thermo Fisher, Waltham, MA; Cat. No. 969056). A targeted cancer panel with selected 25 genes (NextDay Seq-Pan Cancer HotSpot Panel kit, CureSeq Inc.) was used for a deep sequencing of the The Acrometrix Oncology Hotspot Control DNA as previously described [22,34]. In brief, 10 ng of control DNA was amplified and ligated with barcoded and adaptors with the library prep kit (NextDay Seq-Pan Cancer HotSpot Panel kit, CureSeq Inc.). The prepared library was cleaned up using magnetic beads and resuspended in 1x low-TE buffer, followed by qualitative and quantitative electrophoretic analysis by High Sensitivity DNA chip (Agilent Technologies, Santa Clara, CA; Cat. No. 5067–4626). After the emulsion PCR and library enrichment, the prepared library was sequenced using an Ion 314 v2 Chip (Thermo Fisher), and sequenced on an Ion Torrent™ PGM sequencer. The generated sequencing data was processed with MGE from data submission to data distribution as described above.

Access to MGE and ELECTRO

MGE and ELECTRO are available for purchase at CureSeq Inc. (www.cureseq.com, Cat #: SKU#: CS-MGE-01). The register is allowed through the administrator and the administrator will create an account upon request. The account credentials will be given for the user to access the application. Also, the application is protected by virtual private network (VPN), and the address for VPN access will also be provided by administrator. MGE is a smartphone application so a mobile device is used for MGE, and ELECTRO can be used by PHP path installed in a personal computer. Additionally, the user ID and password for ELECTRO is embedded in the system.

Results and discussion

Actual data process with sequencing data

Once the sequencing reaction was completed, the MGE smartphone application notifies it by email. Next, MGE saves the data into its database, and execute DanPA (CureSeq Inc.), a variant
caller specifically coded to call variants from targeted sequencing experiments, previously annotated in the COSMIC database [35]. MGE transfer the.bam and .bai files from the PGM sequencer server to the MGE’s main server and send an alert to the bioinformaticians. The mutation data was curated by using ELECTRO.

We used a 25-gene targeted cancer panel aiming to detect clinically relevant mutations [22]. Thus, we designed our variant detecting algorithm for detecting known and reported mutations rather than un-validated (both technically and clinically) variants. That is why we decided to focus on mutations registered in the COSMIC database, one of the most extensive and robust cancer-related, somatic mutation repository with approximately 3.5 million mutations reported and registered at COSMIC database. If users want to use other variant callers such as GATK or MuTect [31–33], MGE also supports them.

Data review from submitted data

By checking the data under ELECTRO, bioinformaticians can review the sequencing results easily and make a comment for communicating with researchers, medical doctors, or other bioinformaticians.

First, although our variant caller algorithm filters out most of variants located within homopolymer regions (to avoid false positives in those regions, caused by the difficulties of the Ion Torrent PGM chemistry to resolve accurately the insertion/deletions (indels) at homopolymer regions), special attention was paid while reviewing such variants located in a tandem repeat or a homopolymer region [36]. Second, MGE database includes artificial intelligence (AI) features that allows the identification of false positive variants specific for a given sequencing panel. If during the variant call, MGE detects a match between a detected variant and any
Table 1. The identified mutations from the Acrometrix control DNA using MGE and Electro.

| Gene            | COSMIC ID | HGVS name (CDS) | Amino Acid Change |
|-----------------|-----------|-----------------|-------------------|
| ABL1(NM_005157) | COSM12631 | c.742C>G        | p.L248V           |
| ABL1(NM_005157) | COSM12577 | c.749G>A        | p.G250E           |
| ABL1(NM_005157) | COSM12576 | c.757T>C        | p.Y253H           |
| ABL1(NM_005157) | COSM12573 | c.763G>A        | p.E255K           |
| ABL1(NM_005157) | COSM12602 | c.827A>G        | p.D276G           |
| ABL1(NM_005157) | COSM23573 | c.878_879insGCC | p.I293>MP         |
| ABL1(NM_005157) | COSM49071 | c.1150C>A       | p.L384M           |
| ABL1(NM_005157) | COSM12604 | c.1187A>G       | p.H396R           |
| AKT1(NM_005163) | COSM3    | c.1799T>C       | p.G776Y           |
| ALK(NM_004304)  | COSM28065 | c.3824G>A       | p.R1275Q          |
| ALK(NM_004304)  | COSM28055 | c.3522C>A       | p.F1174L          |
| BRAF(NM_004333) | COSM476  | c.1799T>C       | p.G776Y           |
| BRAF(NM_004333) | COSM471  | c.1790T>G       | p.L597R           |
| BRAF(NM_004333) | COSM467  | c.1781A>G       | p.D594G           |
| BRAF(NM_004333) | COSM462  | c.1742A>G       | p.N581S           |
| BRAF(NM_004333) | COSM450  | c.1391G>T       | p.G464V           |
| BRAF(NM_004333) | COSM27986 | c.1380A>G      | p.G460G           |
| EGFR(NM_005228) | COSM13177 | c.2063T>C       | p.L688P           |
| EGFR(NM_005228) | COSM41905 | c.2092G>A       | p.A698T           |
| EGFR(NM_005228) | COSM6239  | c.2156C>G       | p.G719A           |
| EGFR(NM_005228) | COSM13979 | c.2170G>A       | p.G724S           |
| EGFR(NM_005228) | COSM28603 | c.2293G>A       | p.V765M           |
| EGFR(NM_005228) | COSM1451600 | c.2361G>A | p.G787Q          |
| ERBB2(NM_004448) | COSM20959 | c.2324_2325ins12 | p.A775_G776insYVMA |
| ERBB2(NM_004448) | COSM14065 | c.2524G>A       | p.V842I           |
| FLT3(NM_004119) | COSM1166729 | c.2516A>G | p.D839G          |
| FLT3(NM_004119) | COSM783  | c.2503G>T       | p.D835Y           |
| FLT3(NM_004119) | COSM19522 | c.1775T>C       | p.V592A           |
| FLT3(NM_004119) | COSM25248 | c.2492G>A       | p.G831E           |
| GNA11(NM_002067) | COSM21651 | c.547C>T        | p.R138C           |
| GNA11(NM_002067) | COSM52969 | c.626A>T        | p.Q209L           |
| GNAQ(NM_002072) | COSM52975 | c.548G>A        | p.R183Q           |
| GNAQ(NM_002072) | COSM1463119 | c.523A>T    | p.T175S           |
| HRAS(NM_005343) | COSM499   | c.182A>G        | p.Q61R            |
| HRAS(NM_005343) | COSM495   | c.175G>A        | p.A59T            |
| HRAS(NM_005343) | COSM249860 | c.81T>C       | p.H27H            |
| HRAS(NM_005343) | COSM483   | c.35G>T         | p.G12V            |
| IDH1(NM_005896) | COSM28746 | c.395G>A        | p.R132H           |
| IDH1(NM_005896) | COSM1404902 | c.388A>G     | p.I130V           |
| IDH2(NM_002168) | COSM33733 | c.515G>A        | p.R172K           |
| IDH2(NM_002168) | COSM41590 | c.419G>A        | p.R140Q           |
| KRAS(NM_033360) | COSM19940 | c.351A>C        | p.K117N           |
| KRAS(NM_033360) | COSM554   | c.183A>C        | p.Q61H            |
variant record in the mentioned database, a warning message is delivered by MGE into ELECTRO. The history of false positive variants could be optionally used as a filtering factor. As NGS tends to detect the same false positives variants in a recurrent fashion in the same genomic regions, a record of false positives especially at the homopolymer regions resulted extremely helpful to increase the accuracy of variant calling. Third, we also considered the number of times that a single mutation has been previously reported in the COSMIC database as a deciding factor of robust mutation call. The output format of the ELECTRO-MGE mutation file can be customized according to the user’s preferences. The whole analysis was completed within an hour after receiving the raw sequencing result data from the sequencer.

Table 1. (Continued)

| Gene          | COSMIC ID | HGVS name (CDS) | Amino Acid Change |
|---------------|-----------|-----------------|-------------------|
| KRAS(NM_033360) | COSM546   | c.175G>A        | p.A59T            |
| KRAS(NM_033360) | COSM1169214 | c.101C>T       | p.P34L            |
| KRAS(NM_033360) | COSM14208 | c.104C>T        | p.T35I            |
| KRAS(NM_033360) | COSM521   | c.35G>A         | p.G12D            |
| KRAS(NM_033360) | COSM507   | c.24A>G         | p.V8              |
| MAP2K1(NM_002755) | COSM1235478 | c.171G>T      | p.K57N            |
| MAP2K1(NM_002755) | COSM1678546 | c.199G>A       | p.D67N            |
| NRAS(NM_002524)  | COSM584   | c.182A>G        | p.Q61R            |
| NRAS(NM_002524)  | COSM132933 | c.174A>G       | p.T58T            |
| NRAS(NM_002524)  | COSM577   | c.52G>A         | p.A18T            |
| NRAS(NM_002524)  | COSM564   | c.35G>A         | p.G12D            |
| NRAS(NM_002524)  | COSM24850 | c.29G>A         | p.G10E            |
| PIK3CA(NM_006218) | COSM759   | c.1616C>G       | p.P539R           |
| PIK3CA(NM_006218) | COSM760   | c.1624G>A       | p.E542K           |
| PIK3CA(NM_006218) | COSM763   | c.1633G>A       | p.E545K           |
| PIK3CA(NM_006218) | COSM1420865 | c.1640A>G     | p.E547G           |
| PIK3CA(NM_006218) | COSM328026 | c.3110A>G    | p.E1037G          |
| PIK3CA(NM_006218) | COSM775   | c.3140A>G       | p.H1047R          |
| PTEN(NM_000314)   | COSM5109  | c.302T>C        | p.I101T           |
| PTEN(NM_000314)   | COSM5266  | c.314G>T        | p.C105F           |
| PTEN(NM_000314)   | COSM5199  | c.334C>G        | p.L112V           |
| PTEN(NM_000314)   | COSM5123  | c.395G>A        | p.G132D           |
| RET(NM_020975)    | COSM1048  | c.1894_1906>AGCT | p.E632_T636>SS   |
| RET(NM_020975)    | COSM1223553 | c.1942G>A    | p.V648I           |
| SMAD4(NM_005359)  | COSM965   | c.2753T>C       | p.M918T           |
| SMAD4(NM_005359)  | COSM139054 | c.1001A>G      | p.G334R           |
| SMAD4(NM_005359)  | COSM139057 | c.1010A>G      | p.E337G           |
| SMAD4(NM_005359)  | COSM14109 | c.1018A>G       | p.K340E           |
| SMAD4(NM_005359)  | COSM14111 | c.1028C>G       | p.S343*           |
| SMAD4(NM_005359)  | COSM14114 | c.1504A>G       | p.R502G           |
| SMAD4(NM_005359)  | COSM139099 | c.1519A>G      | p.K507E           |
| SMAD4(NM_005359)  | COSM14134 | c.1576G>T       | p.E526*           |
| SMAD4(NM_005359)  | COSM139106 | c.1591C>A      | p.R531R           |
| SMO(NM_005631)    | COSM13145 | c.595C>T        | p.R199W           |
| SMO(NM_005631)    | COSM216037 | c.1234C>T      | p.L412F           |
| SMO(NM_005631)    | COSM13146 | c.1604G>T       | p.W535L           |

https://doi.org/10.1371/journal.pone.0174696.t001
Identified mutations

We used all the variants registered in COSMIC (version 76) database and filtered out germline polymorphisms or sequencing error or false positives in the final validation analyses. We checked all the detected variants using IGV to confirm the true positive results. If necessary, additional validation sequencing was done and analyzed to confirm the results. The library construction panel targeted 83 out of the 500 COSMIC mutations included in the Acrometrix control DNA (Table 1). All 83 mutations were detected, including 7 synonymous and 76 non-synonymous. Among the non-synonymous, 2 were insertions, 1 was a deletion, and 73 were point mutations. Additionally, 74 amplicons out of 75 amplicons in this sample had a sequencing depth of >500x. The results analyzed by MGE were 100% consistent with previous sequencing data of Acrometrix control DNA which was manually analyzed and reviewed [22].

The suspicious false positives variant calls were filtered out by ELECTRO according to the reviewing policy described above. In addition, MGE supports IGV launcher and searching mechanism, and it would boost the sharing of each decision making process of multiple users.

Conclusions

It is highly expected that NGS sequencing information will be available to more and more people who want to know their genetic information, thanks to the significant reduction of a cost and TAT of NGS sequencing. We show that MGE can be an efficient mobile device or cell phone-based genetic controller enabling personalized genome analyses using targeted NGS panel feasible to most of regular laboratories. Current workflows in most laboratories require technicians or bioinformaticians to stay in a laboratory to check the sequencing run quality from the sequencing machine. Then data should be transferred to different types of bioinformatics pipelines used for each laboratory and analyzed by skilled bioinformaticians. All these manual-based sequencing quality check, data transfer, analyses, and review steps prevent the fast and robust genetic analyses. MGE allows us to check all the processes mentioned above into one application of a cellular phone or other mobile device. We used TMAP (Torrent Mapping Alignment Program) for mapping the raw sequencing reads and used DanPA program for variant calling and annotation. DanPA was previously tested in different sequencing projects [22, 37]. We plan to install and use another variant caller in MGE in a near future.

We believe that the automated MGE software, streamlines the genetic data flow from sequencer to clinical report, increasing robustness and efficiency. MGE is a very helpful tool that can help to increase the adoption of NGS technology in CLIA certified laboratories, as well as increase productivity of research, medical, and other life science sequencing laboratories.

Acknowledgments

This study was supported by funds from CureSeq Inc. and Thoracic Oncology Laboratory at University of California San Francisco (UCSF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. D.M.J. and I.J.K. are equity holders and consultants of CureSeq Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: JHY DMJ IJK.
Data curation: JHY TWK PM DMJ IJK.
Formal analysis: JHY TWK PM IJK.
Funding acquisition: DMJ IJK.
Investigation: JHY TWK PM.
Methodology: JHY TWK PM DMJ IJK.
Project administration: DMJ IJK.
Resources: JHY TWK PM DMJ IJK.
Software: JHY TWK IJK.
Supervision: DMJ IJK.
Validation: JHY TWK PM.
Visualization: JHY TWK PM.
Writing – original draft: JHY TWK IJK.
Writing – review & editing: JHY TWK PM DMJ IJK.

References
1. Watson JD, Crick FHC. Molecular structure of nucleic acids. Nature. 1953. pp. 737–738. PMID: 13054692
2. Watson JD, Crick FH. The structure of DNA. Cold Spring Harb Symp Quant Biol. 1953; 18: 123–131. PMID: 13168976
3. Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich Ha. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature. 1986; 324: 163–166. doi:10.1038/324163a0 PMID: 3785382
4. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (80-). 1987; 237: 175–178.
5. Wong C, Dowling CE, Saiki RK, Higuchi RG, Erlich HA, Kazazian HH Jr. Characterization of beta-thalassaemia mutations using direct genomic sequencing of amplified single copy DNA. Nature. 1987; 330: 384–6 ST–Characterization of beta–thalassaemia. doi:10.1038/330384a0 PMID: 3683554
6. Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975; 94.
7. Sanger F, Nicklen S, Coulson a R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74: 5463–7. PMID: 271968
8. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (80-). 1995; 270: 467–470.
9. Favis R, Day JP, Gerry NP, Phelan C, Narod S, Barany F. Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2. Nat Biotechnol. 2000; 18: 561–564. doi:10.1038/75452 PMID: 10802632
10. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002; 415: 436–42. doi:10.1038/415436a PMID: 11807556
11. Shipp M a, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RCT, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature medicine. 2002. pp. 68–74.
12. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530–536. doi:10.1038/415530a PMID: 71934468
13. Porreca GJ, Zhang K, Li JB, Xie B, Austin D, Vassallo SL, et al. Multiplex amplification of large sets of human exons. Nat Methods. 2007; 4: 931–936. doi:10.1038/nmeth1110 PMID: 17934468
14. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008; 452: 872–6. doi:10.1038/nature06884 PMID: 18421352
15. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Eichler EE, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009; 461: 272–6. https://doi.org/10.1038/nature08250 PMID: 19684571

16. Wilhelm BT, Marguerat S, Watt S, Schubert F, Wood V, Goodhead I, et al. Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. Nature. 2008; 453: 1239–1243. https://doi.org/10.1038/nature07002 PMID: 18488015

17. Nagalakshmi U, Wang Z, Waen K, Shou C, Raha D, Gerstein M, et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science. 2008; 320: 1344–9. https://doi.org/10.1126/science.1158441 PMID: 18451266

18. Cloonan N, Forrest AR, Kolle G, Gardiner BB a, Faulkner GJ, Brown MK, et al. Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods. 2008; 5: 613–9. https://doi.org/10.1038/nmeth.1223 PMID: 18516045

19. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5: 621–628. https://doi.org/10.1038/nmeth.1226 PMID: 18516046

20. Lister R, O’Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, et al. Highly Integrated Single-Base Resolution Maps of the Epigenome in Arabidopsis. Cell. 2008; 133: 523–536. https://doi.org/10.1016/j.cell.2008.03.029 PMID: 18423832

21. Hayden EC. The $1,000 genome. Nature. 2014; 507: 295.

22. Mendez P, Dang J, Kim JW, Lee S, Yoon J, Kim T, et al. Comprehensive evaluation and validation of targeted next - generation sequencing performance in two clinical laboratories. 2016; 235–242. https://doi.org/10.1038/j samo.2016.3497 PMID: 27121194

23. Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, et al. Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. PLoS One. 2013; 8.

24. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013; 98.

25. Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015; 1: 40–9. https://doi.org/10.1001/jamaoncol.2014.216 PMID: 26182302

26. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45: 1113–20. https://doi.org/10.1038/ng.2764 PMID: 24071849

27. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502: 333–9. https://doi.org/10.1038/nature12634 PMID: 24132290

28. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012; 4: 136ra68–136ra68. https://doi.org/10.1126/scitranslmed.3003726 PMID: 22649089

29. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. N Engl J Med. 2013; 368: 1199–1209. https://doi.org/10.1056/NEJMoa1213261 PMID: 23484797

30. Jovelet C, Ileana E, Le Deley MC, Motte N, Rosellini S, Romero A, et al. Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial. Clin Cancer Res. 2016; 22: 2960–2968. https://doi.org/10.1158/1078-0432.CCR-15-2470 PMID: 26758560

31. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kerns J, et al. The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20: 1297–1303. https://doi.org/10.1101/gr.107524.110 PMID: 20641999

32. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31: 213–219. https://doi.org/10.1038/nbt.2514 PMID: 23396013

33. Saunders CT, Wong WSW, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: Accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012; 28: 1811–1817. https://doi.org/10.1093/bioinformatics/bts271 PMID: 22581179

34. Kang HC, Kim HK, Lee S, Mendez P, Kim W, Woodard G, et al. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent. Oncotarget. 2016; 7: 8321–8331. https://doi.org/10.18632/oncotarget.7032 PMID: 26824986

35. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: Exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015; 43: D805–D811. https://doi.org/10.1093/nar/gku1075 PMID: 25355519
36. Bragg LM, Stone G, Butler MK, Hugenholtz P, Tyson GW. Shining a Light on Dark Sequencing: Characterising Errors in Ion Torrent PGM Data. PLoS Comput Biol. 2013; 9.

37. Shi X, Wu H, Lu J, Duan H, Liu X, Liang Z. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods. Sci Rep. 2016; 6: 22297. https://doi.org/10.1038/srep22297 PMID: 26923333